J L Gallarda1, E Dragon. 1. Roche Molecular Systems, Inc, Pleasanton, CA 94588, USA. James.Gallarda@Roche.com
Abstract
BACKGROUND: Nucleic acid amplification technology (NAT) is presently being evaluated in US clinical trials to determine the safety and efficacy of mini-pool testing for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) RNA in the blood-donor population. Although the risk for transfusion-transmitted HIV and HCV infection is extremely low, there is still a small chance that blood donated by infected individuals before seroconversion can escape detection by current antibody-based assays. METHODS: This report describes the amplification technologies being used and reviews several issues surrounding NAT-based blood screening. The performance features of NAT and current enzyme immunoassay technologies are compared, and the benefits of NAT in reducing transfusion-transmitted infections are discussed. CONCLUSIONS: The current US clinical trials of mini-pool NAT testing for HIV and HCV RNA have successfully identified preseroconversion infectious blood units. Although the current NAT-based screening systems are semiautomated, mini-pool testing represents an unprecedented innovation among government and nongovernment agencies in the highly regulated blood transfusion industry. Despite cost-effectiveness issues, based on the public perception of infectious diseases acquired through blood transfusion, NAT-based screening of the blood supply is expected to become a standard in transfusion medicine.
BACKGROUND: Nucleic acid amplification technology (NAT) is presently being evaluated in US clinical trials to determine the safety and efficacy of mini-pool testing for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) RNA in the blood-donor population. Although the risk for transfusion-transmitted HIV and HCV infection is extremely low, there is still a small chance that blood donated by infected individuals before seroconversion can escape detection by current antibody-based assays. METHODS: This report describes the amplification technologies being used and reviews several issues surrounding NAT-based blood screening. The performance features of NAT and current enzyme immunoassay technologies are compared, and the benefits of NAT in reducing transfusion-transmitted infections are discussed. CONCLUSIONS: The current US clinical trials of mini-pool NAT testing for HIV and HCV RNA have successfully identified preseroconversion infectious blood units. Although the current NAT-based screening systems are semiautomated, mini-pool testing represents an unprecedented innovation among government and nongovernment agencies in the highly regulated blood transfusion industry. Despite cost-effectiveness issues, based on the public perception of infectious diseases acquired through blood transfusion, NAT-based screening of the blood supply is expected to become a standard in transfusion medicine.
Authors: M P Busch; L L Lee; G A Satten; D R Henrard; H Farzadegan; K E Nelson; S Read; R Y Dodd; L R Petersen Journal: Transfusion Date: 1995-02 Impact factor: 3.157
Authors: F S Nolte; M W Fried; M L Shiffman; A Ferreira-Gonzalez; C T Garrett; E R Schiff; S J Polyak; D R Gretch Journal: J Clin Microbiol Date: 2001-11 Impact factor: 5.948
Authors: Tam T Van; Joseph Miller; David M Warshauer; Erik Reisdorf; Daniel Jernigan; Rosemary Humes; Peter A Shult Journal: J Clin Microbiol Date: 2012-01-11 Impact factor: 5.948
Authors: C Giachetti; J M Linnen; D P Kolk; J Dockter; K Gillotte-Taylor; M Park; M Ho-Sing-Loy; M K McCormick; L T Mimms; S H McDonough Journal: J Clin Microbiol Date: 2002-07 Impact factor: 5.948